GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » PB Ratio

I-MAB (IMAB) PB Ratio

: 0.44 (As of Today)
View and export this data going back to 2020. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-18), I-MAB's share price is $1.80. I-MAB's Book Value per Share for the quarter that ended in Jun. 2023 was $4.14. Hence, I-MAB's PB Ratio of today is 0.44.

The historical rank and industry rank for I-MAB's PB Ratio or its related term are showing as below:

IMAB' s PB Ratio Range Over the Past 10 Years
Min: 0.24   Med: 1   Max: 6.8
Current: 0.43

During the past 6 years, I-MAB's highest PB Ratio was 6.80. The lowest was 0.24. And the median was 1.00.

IMAB's PB Ratio is ranked better than
92.99% of 1312 companies
in the Biotechnology industry
Industry Median: 2.39 vs IMAB: 0.43

During the past 12 months, I-MAB's average Book Value Per Share Growth Rate was -42.70% per year.

Back to Basics: PB Ratio


I-MAB PB Ratio Historical Data

The historical data trend for I-MAB's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PB Ratio
Premium Member Only - - 3.93 5.29 0.83

I-MAB Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.60 5.29 1.57 0.83 0.72

Competitive Comparison

For the Biotechnology subindustry, I-MAB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, I-MAB's PB Ratio distribution charts can be found below:

* The bar in red indicates where I-MAB's PB Ratio falls into.



I-MAB PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

I-MAB's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2023)
=1.80/4.135
=0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


I-MAB  (NAS:IMAB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


I-MAB PB Ratio Related Terms

Thank you for viewing the detailed overview of I-MAB's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB (IMAB) Business Description

Traded in Other Exchanges
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.